Midas Pharma obtains CEP for Clofazimine

Midas Pharma was recently granted with a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient Clofazimine.

Midas Pharma -with its European based manufacturer- is regularly producing on several tons scale and is proud to represent therewith the only major source from Europe.

Clofazimine with its intense red color is established since several decades as an antimycobacterial for treatment of leprosy - in particular in combination with Dapsone and/or Rifampicin.

Clofazimine which is therefore listed as a WHO Essential Medicine holds furthermore orphan drug status for use in multidrug-resistant strains of Mycobacterium tuberculosis.

If you are interested in further information about the product, please contact us.

Your Contact

Dr. Matthias Hassemer

Dr. Matthias Hassemer

Custom Synthesis & Technology Transfer
Head of Product Management

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Send E-Mail

Share this page